Scientists assessed the safety and clinical activity of ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.
[Lancet]